share_log

Addex Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

Addex Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

Addex Therapeutics | 6-K：外國發行人報告（業績相關）
美股SEC公告 ·  2024/11/22 19:06

Moomoo AI 已提取核心訊息

Addex Therapeutics reported financial results for Q3 2024, with a net profit of CHF 8.3 million for the nine months ended September 30, 2024, primarily driven by the Neurosterix Transaction completed in April 2024. The transaction generated proceeds of CHF 5.0 million in cash and a 20% equity stake in Neurosterix valued at CHF 9.4 million.Revenue from continuing operations decreased to CHF 0.4 million for the nine months, compared to CHF 1.5 million in the same period of 2023. Operating costs from continuing operations reduced to CHF 2.7 million from CHF 3.0 million, mainly due to lower external R&D costs and D&O insurance expenses. Cash and cash equivalents stood at CHF 3.3 million as of September 30, 2024.The company retained its partnerships with Janssen and Indivior, along with clinical-stage assets including dipraglurant for Parkinson's disease and post-stroke recovery. In August 2024, Indivior selected a compound for substance use disorder development, while Addex retained rights to develop a GABAB PAM program for chronic cough.
Addex Therapeutics reported financial results for Q3 2024, with a net profit of CHF 8.3 million for the nine months ended September 30, 2024, primarily driven by the Neurosterix Transaction completed in April 2024. The transaction generated proceeds of CHF 5.0 million in cash and a 20% equity stake in Neurosterix valued at CHF 9.4 million.Revenue from continuing operations decreased to CHF 0.4 million for the nine months, compared to CHF 1.5 million in the same period of 2023. Operating costs from continuing operations reduced to CHF 2.7 million from CHF 3.0 million, mainly due to lower external R&D costs and D&O insurance expenses. Cash and cash equivalents stood at CHF 3.3 million as of September 30, 2024.The company retained its partnerships with Janssen and Indivior, along with clinical-stage assets including dipraglurant for Parkinson's disease and post-stroke recovery. In August 2024, Indivior selected a compound for substance use disorder development, while Addex retained rights to develop a GABAB PAM program for chronic cough.
Addex Therapeutics公佈了2024年第三季度的財務結果，截至2024年9月30日的九個月內凈利潤爲830萬瑞士法郎，主要得益於2024年4月完成的Neurosterix交易。該交易產生了500萬瑞士法郎的現金收入，以及在Neurosterix中持有20%股權，估值爲940萬瑞士法郎。持續經營的營業收入爲40萬瑞士法郎，較2023年同期的150萬瑞士法郎有所下降。持續經營的運營成本從300萬瑞士法郎減少至270萬瑞士法郎，主要由於外部研發成本和D&O保險費用的降低。截至2024年9月30日，現金及現金等價物爲330萬瑞士法郎。公司與強生和Indivior保持合作關係，擁有包括用於治療帕金森病和中風後恢復的dipraglurant在內的臨牀階段資產。2024年8月，Indivior選擇了一種用於物質使用障礙開發的Compound，而Addex保留了開發用於慢性咳嗽的GABAb PAm項目的權利。
Addex Therapeutics公佈了2024年第三季度的財務結果，截至2024年9月30日的九個月內凈利潤爲830萬瑞士法郎，主要得益於2024年4月完成的Neurosterix交易。該交易產生了500萬瑞士法郎的現金收入，以及在Neurosterix中持有20%股權，估值爲940萬瑞士法郎。持續經營的營業收入爲40萬瑞士法郎，較2023年同期的150萬瑞士法郎有所下降。持續經營的運營成本從300萬瑞士法郎減少至270萬瑞士法郎，主要由於外部研發成本和D&O保險費用的降低。截至2024年9月30日，現金及現金等價物爲330萬瑞士法郎。公司與強生和Indivior保持合作關係，擁有包括用於治療帕金森病和中風後恢復的dipraglurant在內的臨牀階段資產。2024年8月，Indivior選擇了一種用於物質使用障礙開發的Compound，而Addex保留了開發用於慢性咳嗽的GABAb PAm項目的權利。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Dogwood Therapeutics
    DWTX
    -- 13.350
    Transcode Therapeutics
    RNAZ
    -- 5.500
    Evaxion Biotech
    EVAX
    -- 3.640
    Hepion Pharmaceuticals
    HEPA
    -- 0.2000
    Nutriband
    NTRB
    -- 9.900
    解鎖完整榜單
    熱門中概股
    追蹤最熱門的中概股實時資訊。
    熱門討論
    中美談話新契機，通脹不再？
    🎙️討論： 1. 特朗普上台後，對華政策如何影響中國資產？ 2. 美股市場通脹風險下降，哪些板塊受益？ 展开
    中國將在明年採取 “適度寬鬆” 的貨幣政策，這是自2011年以來首次轉向寬鬆